Pyxis Oncology to Attend Upcoming Investor Conferences

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Nov 03 2025

0mins

Source: Globenewswire

Upcoming Investor Conferences: Pyxis Oncology will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10 and the Stifel 2025 Healthcare Conference on November 11, both featuring fireside chats.
Company Overview: Pyxis Oncology is a clinical-stage biopharmaceutical company focused on developing therapeutics for difficult-to-treat cancers, with its lead candidate, MICVO, targeting solid tumors through a unique mechanism of action.
Lead Candidate Details: MICVO is an antibody drug conjugate designed to treat solid tumors by directly killing tumor cells, inducing a bystander effect, and promoting immunogenic cell death, currently in Phase 1 clinical studies.
Focus on Patient Outcomes: The company aims to improve outcomes for patients with recurrent and metastatic head and neck squamous cell carcinoma and contribute to advancements in cancer treatment.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Let AI Trade for You

Auto Trading Task on NVDA?

Get Started Free